Bos J L, Verlaan-de Vries M, van der Eb A J, Janssen J W, Delwel R, Löwenberg B, Colly L P
Blood. 1987 Apr;69(4):1237-41.
Using synthetic oligomers we investigated fresh samples of acute myeloid leukemia (AML) for the presence of mutated ras oncogenes. Our original results showed that five of eight samples contained a mutation in codon 13 of the N-ras gene. In a subsequent study involving 37 samples, we found only one N-ras-13 mutation, and, in addition, mutations in codon 61 of the N-ras gene in four cases and a mutation in codon 12 of the Ki-ras gene in two cases. Amplification of ras genes was not observed. We conclude that in approximately 20% to 25% of AML cases, a mutated ras oncogene is present, predominantly the N-ras gene. The occurrence of mutations does not correlate with the cytological features of the leukemia.
我们使用合成寡聚体对急性髓系白血病(AML)新鲜样本进行研究,以检测是否存在突变的ras癌基因。我们最初的结果显示,8个样本中有5个在N-ras基因的第13密码子处存在突变。在随后一项涉及37个样本的研究中,我们仅发现1个N-ras-13突变,此外,4例样本中存在N-ras基因第61密码子的突变,2例样本中存在Ki-ras基因第12密码子的突变。未观察到ras基因的扩增。我们得出结论,在大约20%至25%的AML病例中存在突变的ras癌基因,主要是N-ras基因。突变的发生与白血病的细胞学特征无关。